文献速递甲状腺疾病

COVID-19患者甲状腺血管紧张素转换酶2蛋白表达与甲状腺功能检查:回顾性病例系列与前瞻性队列研究结果

Thyroidal Angiotensin-Converting Enzyme 2 Protein Expression and Thyroid Function Tests in Patients with COVID-19: Results from a Retrospective Case Series and a Prospective Cohort Study.
PubMed 文献 · Thyroid · 2023-01-01

回顾性分析23例死于重型COVID-19患者的甲状腺组织,免疫组化检测ACE2表达并观察病理改变;前瞻性队列纳入153例确诊SARS-CoV-2感染者,按重型(插管、重症监护)与中间组比较甲状腺功能检查。结果显示87%死亡患者甲状腺组织ACE2表达阳性,无SARS-CoV-2感染患者正常甲状腺组织无ACE2蛋白表达;约半数重型患者游离三碘甲状腺原氨酸(fT3)降低,低fT3合并促甲状腺激素(TSH)≤0.5 mU/L与致死性结局显著相关。

要点

  • 87%死于COVID-19的患者甲状腺组织ACE2免疫组化染色阳性
  • 无SARS-CoV-2感染者的正常甲状腺组织未见ACE2蛋白表达
  • 约半数重型COVID-19患者fT3水平降低

核心结论

  • 死亡COVID-19患者甲状腺ACE2免疫染色阳性比例高,而无SARS-CoV-2感染者正常甲状腺组织无ACE2表达,提示甲状腺参与COVID-19,但甲状腺ACE2的致病作用尚需进一步研究。
  • 在重型SARS-CoV-2感染队列中,fT3异常及TSH≤0.5 mU/L与致死性结局相关。
  • 因此,对重型COVID-19患者评估甲状腺功能检查至关重要。

研究设计与样本

  • 回顾性病例系列分析23例死于COVID-19患者的甲状腺组织,行组织病理学检查及免疫组化染色检测ACE2表达。
  • 前瞻性队列研究纳入153例确诊SARS-CoV-2感染患者,评估甲状腺功能检查,并分为重型组(插管、重症监护治疗)与中间组。
  • 试验注册:慕尼黑大学医院COVID-19登记(CORKUM),WHO试验ID DRKS00021225。

主要发现

  • 87%的死亡COVID-19患者甲状腺组织检测到ACE2表达;无SARS-CoV-2感染者的正常甲状腺组织未见ACE2蛋白表达。
  • 约半数重型COVID-19患者fT3水平降低。
  • 低fT3合并TSH与致死性结局显著相关。
  • TSH≤0.5 mU/L与重型SARS-CoV-2感染患者致死性结局相关。

关键数值与推荐

  • 甲状腺ACE2表达:死亡COVID-19患者中87%免疫组化阳性。
  • 无SARS-CoV-2感染者正常甲状腺组织:ACE2蛋白表达阴性。
  • 重型COVID-19患者中约半数fT3降低。
  • 低fT3合并TSH及TSH≤0.5 mU/L与致死性结局显著相关。

临床怎么用

  • 作者认为,对重型COVID-19患者评估甲状腺功能检查在治疗中至关重要。
  • 原文未据此给出其他推荐。

局限性

  • 原文指出甲状腺ACE2在COVID-19中的致病作用尚需进一步研究才能明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Infection with SARS-CoV-2 has initially been known as a respiratory disease but in the course of the pandemic the understanding has emerged that severity is owing to fatal inflammatory responses apart from lung injury. In this context, endocrine disorders such as thyroiditis as well as pituitary dysfunction in addition to nonthyroidal illness syndrome have been described. Furthermore, angiotensin-converting enzyme 2 (ACE2), the SARS-CoV-2 cell receptor, has been detected in most endocrine tissues, including the thyroid gland. Objective: To evaluate histopathologic changes and compare thyroidal ACE2 protein expression in thyroid tissue from patients who died from severe COVID-19 with thyroid tissue from patients without SARS-CoV-2 infection in a retrospective case series. Furthermore, to assess and compare alterations in thyroid function tests (TFTs) between patients with or without SARS-CoV-2 infection as well as association of TFTs with the severity of the disease in a prospective cohort study. Methods: Thyroid tissue of deceased COVID-19 patients (n = 23) was analyzed for histopathology and ACE2 expression by immunohistochemical staining. A total of 153 patients with confirmed SARS-CoV-2 were evaluated regarding TFTs and divided into a severe (intubation, intensive care treatment) and an intermediate group. Results: Thyroidal ACE2 expression was detected in 87% of the deceased COVID-19 patients. Normal thyroid tissue from patients without SARS-CoV-2 infection showed no ACE2 protein expression. Half of the severely ill COVID-19 patients had low free triiodothyronine (fT3) levels. Combination of low fT3 and thyrotropin (TSH) was associated significantly with deadly disease. Conclusion: The high percentage of positive ACE2 immunostaining in deceased patients compared with normal thyroid tissue of patients without SARS-CoV-2 infection suggests involvement of the thyroid in COVID-19, although further research will have to show the pathogenic role of thyroidal ACE2 in COVID-19. Abnormal fT3 and a TSH of ≤0.5 mU/L were associated with a fatal outcome in our severely ill SARS-CoV-2 patient cohort. Therefore, assessment of TFTs is crucial in the treatment of severely ill COVID-19 patients. Trial Registration: COVID-19 Registry of the LMU University Hospital Munich (CORKUM), WHO trial ID DRKS00021225.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Koehler VF, Knösel T, Hasmann SE, et al. Thyroidal Angiotensin-Converting Enzyme 2 Protein Expression and Thyroid Function Tests in Patients with COVID-19: Results from a Retrospective Case Series and a Prospective Cohort Study. Thyroid. 2023. PMID: 36453232. doi:10.1089/thy.2022.0229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。